Compare Danaher Corporation (DHR) vs iShares International Treasury Bond ETF (IGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs iShares International Treasury Bond ETF — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while iShares International Treasury Bond ETF trades at $39.74 (market cap $1.30B). The key difference: Danaher Corporation is far larger — about 117.6× iShares International Treasury Bond ETF's market cap, and Danaher Corporation pays a 0.74% dividend while iShares International Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and iShares International Treasury Bond ETF for 92 Days on average.
| DHR | IGOV | |
|---|---|---|
Market Cap | $152.87B | $1.30B |
Volume | 5,228,698 | 693,740 |
Sector | Health | Fixed Income |
52-Week High | $242.05 | $42.99 |
52-Week Low | $161.91 | $39.65 |
Typical Hold Time | 69 Days | 92 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
IGOV trades at $39.73, up 0.08% on the day, with a bearish technical signal from moving averages but neutral oscillators. Key financial ratios such as P/E and P/S are not available in the provided data. Recent news highlights rising global bond yields, which may impact interest-rate-sensitive assets.
The outlook remains cautious due to bearish technicals and macroeconomic pressures from higher yields. Investment opportunities hinge on undisclosed fundamentals, while risks include market volatility and interest rate sensitivity. Investors should await clearer financial disclosures for a full assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →
